1. Pink Sheet
  2. >>Market Access

What Exactly Is A ‘Small Biotech’? US Medicare Agency Will Try To Spell It Out

 
• By Michael McCaughan

CMS’s new price negotiation authority has an exemption for ‘small biotech’ companies. The agency’s implementation plan suggests that will be a tricky concept to define.

big and small execs
Who are you calling small? CMS will have to decide. • Source: Shutterstock

The US Medicare agency’s implementation plan for the recently enacted price negotiation authority suggests that applying the legislative exemption for “small biotech” companies may be a particularly complicated part of the process.

The Centers for Medicare & Medicaid Services released a timeline for providing guidance on key elements on the Inflation Reduction Act’s price cutting authority on 11 January. The agency is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

MAHA Commission Outlines Enhanced Research On Drug Safety In Children

 
• By Cathy Kelly

Research would include initiatives on reproducing industry-sponsored studies, postmarket surveillance, and studies of long-term neurodevelopmental and metabolic outcomes for commonly prescribed pediatric drugs.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.